Diminished renal function and the incidence of heart failure

Current Cardiology Reviews

Volumn 5, Issue 3, 2009, Pages 223-227

  Ärnlöv, Johan ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Högskolan Dalarna ^*  (Sweden)

Author keywords

Albuminuria; Creatinine; Cystatin C; Glomerular filtration rate; Heart failure; Kidney disease

Indexed keywords

CREATININE; CYSTATIN C; LOSARTAN; RAMIPRIL;

ALBUMINURIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 70449627805     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340309788970388     Document Type: Review

References (54)

1. Ronco C, House AA, Haapio M. Cardiorenal syndrome: Refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34(5): 957-962
2. Hillege HL, Girbes AR, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210 (Pubitemid 30451778)
3. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671-678 (Pubitemid 43754331)
4. Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 2004; 44: 1593-1600 (Pubitemid 39369791)
5. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004; 15: 2195-2203
6. Smith GL, Shlipak MG, Havranek EP, et al. Race and renal impairment in heart failure: Mortality in blacks versus whites. Circulation 2005; 111: 1270-1277
7. Ezekowitz J, McAlister FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol 2004; 44: 1587-1592 (Pubitemid 39369790)
8. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009
9. van de Wal RM, Asselbergs FW, Plokker HW, et al. High prevalence of microalbuminuria in chronic heart failure patients. J Card Fail 2005; 11: 602-606 (Pubitemid 41463731)
10. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996
11. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens 2004; 13: 163-170 (Pubitemid 38373138)
12. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 2003; 42: 1050-1065 (Pubitemid 37413751)
13. Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006; 17: 2034-2047 (Pubitemid 44036188)
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470 (Pubitemid 29135798)
16. Fliser D, Ritz E. Serum cystatin c concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001; 37: 79-83. (Pubitemid 32055022)
17. Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: The cardiovascular health study. J Am Coll Cardiol 2000; 35: 1628-1637 (Pubitemid 30307510)
18. Fried LF, Shlipak MG, Crump C, et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. J Am Coll Cardiol 2003; 41: 1364-1372 (Pubitemid 36438998)
19. Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insufficiency and risk of congestive heart failure in men and women > or =70 years of age. Am J Cardiol 2003; 92: 682-686
20. Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: The atherosclerosis risk in communities (aric) study. J Am Soc Nephrol 2007; 18: 1307-1315 (Pubitemid 46536917)
21. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The hope randomized trial. Ann Intern Med 2001; 134: 629-636 (Pubitemid 32322240)
22. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
23. Ruilope LM, Zanchetti A, Julius S, et al. Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the value trial. J Hypertens 2007; 25: 1473-1479 (Pubitemid 46918836)
24. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Predictors of heart failure among women with coronary disease. Circulation 2004; 110: 1424-1430 (Pubitemid 39263737)
25. Bertoni AG, Hundley WG, Massing MW, Bonds DE, Burke GL, Goff DC, Jr. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004; 27: 699-703.
26. Remuzzi G, Ruggenenti P, Perna A, et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the renaal trial results. J Am Soc Nephrol 2004; 15: 3117-3125 (Pubitemid 39578844)
27. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin c: Implications for the assessment of glomerular filtration rate. Clin Chem 1998; 44: 1535-1539 (Pubitemid 28309116)
28. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin c measured by automated immunoassay: A more sensitive marker of changes in gfr than serum creatinine. Kidney Int 1995; 47: 312-318
29. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772 (Pubitemid 46580250)
30. Laterza OF, Price CP, Scott MG. Cystatin c: An improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707.
31. Massey D. Commentary: Clinical diagnostic use of cystatin c. J Clin Lab Anal 2004; 18: 55-60. (Pubitemid 38177005)
32. Sarnak MJ, Katz R, Stehman-Breen CO, et al. Cystatin c concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005; 142: 497-505. (Pubitemid 40490915)
33. Shlipak MG, Katz R, Sarnak MJ, et al. Cystatin c and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237-246 (Pubitemid 46768607)
34. Bibbins-Domingo K, Chertow GM, Fried LF, et al. Renal function and heart failure risk in older black and white individuals: The health, aging, and body composition study. Arch Intern Med 2006; 166: 1396-1402. (Pubitemid 44036352)
35. Djousse L, Kurth T, Gaziano JM. Cystatin c and risk of heart failure in the physicians' health study (phs). Am Heart J 2008; 155: 82-86 (Pubitemid 350234775)
36. Moran A, Katz R, Smith NL, et al. Cystatin c concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008; 14: 19-26.
37. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin c: A novel predictor of outcome in suspected or confirmed non-st-elevation acute coronary syndrome. Circulation 2004; 110: 2342-2348 (Pubitemid 39407337)
38. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin c in patients with coronary heart disease and risk for secondary cardiovascular events: More than simply a marker of glomerular filtration rate. Clin Chem 2005; 51: 321-327 (Pubitemid 40175801)
39. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin c with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: Data from the heart and soul study. Circulation 2007; 115: 173-179 (Pubitemid 46105715)
40. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia 1989; 32: 219-226
41. Arnlov J, Evans JC, Meigs JB, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: The framingham heart study. Circulation 2005; 112: 969-975 (Pubitemid 41170264)
42. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426 (Pubitemid 32681484)
43. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, c-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Jama 2005; 293: 1609-1616 (Pubitemid 40471791)
44. Ingelsson E, Sundstrom J, Lind L, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J 2007; 28: 1739-1745 (Pubitemid 47227087)
45. Hockensmith ML, Estacio RO, Mehler P, et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail 2004; 10: 126-131 (Pubitemid 38858073)
46. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: Observations from the diabhycar (type 2 diabetes, hypertension, cardiovascular events and ramipril) study. Diabetes Care 2003; 26: 855-860 (Pubitemid 36929355)
47. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the heart outcomes prevention evaluation (hope) study. Circulation 2003; 107: 1284-1290 (Pubitemid 36314412)
48. Okin PM, Wachtell K, Devereux RB, et al. Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: The life study. Am J Hypertens 2008; 21: 273-279 (Pubitemid 351323279)
49. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927 (Pubitemid 39128617)
50. Tonelli M, Jose P, Curhan G, Sacks F, Braunwald E, Pfeffer M. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: Analysis of a previously conducted randomised trial. BMJ 2006; 332: 26.
51. Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007; 115: 928-935 (Pubitemid 46294733)
52. Pencina MJ, D' Agostino RB S, D' Agostino RB J, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the roc curve to reclassification and beyond. Stat Med 2007; 27(2): 157-172
53. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 2004; 159: 882-890 (Pubitemid 38657490)
54. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006; 355: 2615-2617 (Pubitemid 44969120)